Summary.-The levels of polyamines (putrescine, spermidine and spermine) in erythrocytes and plasma were studied using Cloudman S-91 melanoma grown in the lungs of DBA/2 mice. Polyamine levels and the numbers of tumour-cell colonies in the lungs were determined at weekly intervals. Putrescine levels in both erythrocytes and plasma significantly increased 1 week after tumour inoculation. Three weeks after inoculation, however, putrescine levels in the erythrocytes showed a greater increase than those in plasma. Spermidine and spermine levels were initially high at 2 weeks in plasma and at 4 weeks in erythrocytes. However, by 6 weeks the spermidine levels showed a greater increase in erythrocytes than in plasma. These data suggest that erythrocytes may absorb and store polyamines released into the circulation.
THE NATURALLY occurring polyamines are known to have important regulatory functions in growth and proliferation of cells (Cohen, 1971; Bachrach, 1973) . Since Russell (1971) first reported that cancer patients excreted an increased amount of polyamines in their urine, a number of papers have been published on raised polyamine levels in urine (Dreyfuss et al., 1975; Lipton et al., 1975; Waalkes et al., 1975) and plasma or serum (Nishioka & Romsdahl, 1974; Russell & Russell, 1975; Nishioka & Romsdahl, 1977; Nishioka et al., 1977; Chaisiri et al., 1979) of cancer patients. At present, however, the clinical application of polyamine determinations as a diagnostic tool for cancer detection has been limited by the low sensitivity and lack of specificity of polyamine detection in urine or plasma.
Recently, high polyamine levels have been found in erythrocytes from patients with cancer (Saeki et al., 1978; Cooper et al., 1978) . These reports dealt with a limited number of patients. At this time, very little information is available on the level of polyamines in erythrocytes during the cancer state in humans. Although some reports also indicated high levels of polyamines in tumour tissues or urine of tumour-transplanted animals (Neish & Key, 1967; Russell & Levy, 1971; Andersson & Heby, 1972) and during carcinogenesis (Fujita et al., 1976 (Fujita et al., , 1978 Perin & Sessa, 1978; Scalabrino et al., 1978) , no values have been reported for polyamines in whole blood of tumour-bearing animals. Therefore, using an animal model system, we investigated the fluctuation of polyamine levels in erythrocytes and plasma at various times after inoculation of melanoma cells. Based on these results, an attempt was made to study erythrocyte polyamine levels relative to plasma polyamine levels in cancer patients, and to examine the potential usefulness of erythrocyte polyamines as biological markers for cancer.
MATERIALS AND METHODS
Experimental mouse melanoma.-Male inbred DBA/2 mice, aged 5 weeks (18-21 g) were purchased from Timco Breeding Laboratories (Houston, Texas, U.S.A.), and fed a standard laboratory diet ad libitum.
The melanoma cells used were maintained in tissue culture in Eagle's minimum essential medium (MEM) supplemented with 10% foetal calf serum (Gibco, Grand Island, N.Y., U.S.A.). One-tenth ml of the cultured cells (106 cells/ml) suspended in MEM was injected into the tail vein. Each week thereafter at least 6 mice were sacrificed to collect blood. The lungs were examined macroscopically for pigmented melanoma colonies, which were then counted. Control mice were injected with 0-1 ml of MEM and sacrificed in groups of 4 (minimum). Blood was drawn from retroorbital plexus under ether anaesthesia and placed in heparinized tubes. All blood was collected between 10.00 and 11.00 to avoid difference due to circadian rhythm (Halberg et al., 1976) .
Patients with solid tumours.-The 52 (18 M; 34 F) preoperative patients examined (mean age, 59) with solid tumours (breast, 16; colorectum, 14; lung, 8; melanoma, 7; miscellaneous, 7) had no previous treatments, blood transfusions or other diseases. The control subjects were 11 (5 M; 6 F) healthy closely age-matched individuals (mean age, 55). Premenopausal females were excluded from this study due to known fluctuation in polyamine levels during the menstrual cycle . Heparinized blood was collected during the fasting state in the morning.
Preparation of samples and determination of polyamines-.Whole blood was immediately centrifuged at 500 g for 20 min after collection. The plasma was then removed for polyamine assay, and the buffy coat leucocytes were carefully aspirated from the erythrocytes (Cooper, et al., 1978; Saeki, et al., 1978) .
Aliquots of plasmna (0-3-0-35 ml from the mouse and 5 0 ml from the human) were used for polyamine analysis. The erythrocytes were subsequently washed with 3 volumes of cold physiological saline, centrifuged, and the buffy coat leucocytes aspirated as above. This procedure was repeated twice more. After thoroughly mixing the packed erythrocytes, aliquots of the erythrocyte fraction (0-2 ml from mouse sample and 1I0 ml from human sample) were used for preparation of polyamine samples.
Plasma and erythrocytes thus obtained were treated with trichloroacetic acid (TCA) as follows, according to the procedures of Durie et al. (1977) with some modifications.
Plasma was mixed with 100% TCA to a final concentration of 500 TCA. An additional volume of 50o TCA (1-0 ml for mouse sample, 3 0 ml for human sample) was then added to the plasma. In the erythrocyte samples, 5%
TCA solution was added to the erythrocytes first, followed by the 100% TCA, to avoid insufficient mixing which occurs if 100% TCA is added directly to erythrocytes. The samples were then mixed thoroughly for a minimum of 3 min and left standing at 4°C for 30 min. After centrifugation at 5,000 g for 20 min, the supernatants were collected and pellets reextracted twice with 500 TCA as above. The supernatants were combined and lyophilized. These samples were hydrolysed in 6N HCI for 16 h at 104°C, extracted twice with ether, and again lyophilized. The residues were dissolved in 0 5 N HCI and analysed for polyamines, using a Durrum D-500 high-pressure amino acid analyser (Russell & Russell, 1975; Cooper et al., 1976 As shown in Fig. 1 , putrescine levels in both erythrocytes and plasma significantly increased as early as 1 week after inoculation, reaching the maximum level at 4 weeks. However, after 3 weeks putrescine levels in erythrocytes showed a much greater increase than those in plasma. Putrescine levels in erythrocytes were 2-4-3-5 x those of controls during the 3rd to 7th week after inoculation, whereas in plasma they were 1-6-2*3 x those of controls at corresponding weeks. Figs 2 and 3 show that both spermidine and spermine levels in plasma significantly increased 2 weeks after inoculation, and remained at this level until 5 weeks. Subsequently, mild decreases of spermidine and spermine levels were seen. On the other hand, spermidine and spermine levels in erythrocytes significantly increased at 4 weeks, continuing markedly to increase during the observation. Beyond 6 weeks the spermidine and spermine levels in erythro- cytes increased much more than in plasma.
For example, spermidine levels in erythrocytes were 4-6 and 5-2 times the controls at 6 and 7 weeks after inoculation, respectively, whereas in plasma they were 2*6 and 2 2 times the controls at the corresponding weeks. Similarly, spermine levels in erythrocytes were 2-0 and 3 0 times those of the controls at 6 and 7 weeks, respectively, while levels in plasma were 1P7 and 2-2 times those of the controls at the corresponding weeks.
Erythrocyte and plasma polyamine levels in patients with solid tumours and in control subjects As presented in Table II , the levels of putrescine, spermidine and spermine were raised in erythrocytes of more than 60% of the patients with cancer, and significantly higher than those in control subjects. On the other hand, less than 30% of the cancer patients had raised levels of putrescine, spermidine, and spermine in their plasma. While spermidine levels of plasma from cancer patients were found to be significantly higher than those of control subjects, putrescine and spermine levels from cancer patients were not significantly higher than controls. In comparing frequencies of high polyamine levels between erythrocytes and plasma, there were significantly more high levels of putrescine, spermidine and spermine in erythrocytes than in plasma (X2 analysis: putrescine and spermine, P < 0-0005; spermidine, P < 0 00025).
DISCUSSION
It was recently demonstrated Cooper et al., 1976; Saeki et al., 1978 ) that erythrocytes contain more than 80% of the spermidine and more than 7000 of the spermine in whole blood. Based on these findings, preliminary studies (Cooper et al., 1978; Saeki et al., 1978) have demonstrated that erythrocyte polyamine levels from patients with solid tumours were raised. These preliminary human studies seemed to warrant an investigation of the behaviour of erythrocyte polyamines in an animal tumour model. In our animal model, putrescine was simultaneously high in both plasma and erythrocytes during the early phases of melanoma growth, whereas significant increases in spermidine and spermine levels in plasma were detected earlier Ilhan in erythrocytes. However, the increased levels of putrescine, spermidine and spermine in erythrocytes were much greater than in plasma in the latter phases of tumour growth. This observation indicates that erythrocytes from patients with solid tumours may absorb and store the polyamines released from growing tumours into circulating blood. Cooper et al. (1978) have suggested that the polyamines produced by tumours were absorbed into erythro-754, cytes to maintain equilibration of polyamines among tumours, plasma, erythrocytes and leucocytes. Saeki et al. (1978) also pointed out that erythrocytes may work as polyamine carriers in the systemic circulation.
The results from our animal studies were used to design our investigation of polyamine levels in cancer patients. Erythrocyte polyamine levels in patients with solid tumours were significantly higher than in control subjects. We also found that the frequency of high polyamine levels in erythrocytes was significantly greater than in plasma. Measuring the polyamine levels in erythrocytes seems to be much more sensitive for the detection of cancer than measuring the levels in plasma. Although Cooper et al. (1978) separated whole blood into the fractions of erythrocytes, mononuclear leucocytes, polymorphonuclear leucocytes, platelets and plasma for polyamine analysis, only one patient with lung cancer was examined. Saeki et al. (1978) reported raised polyamine levels in erythrocytes from 10 patients with solid tumours, although erythrocyte polyamine levels were not compared with plasma levels.
The question raised by these results is where the circulating polyamines in plasma are bound and localized. In examining polyamine levels in erythrocytes ageseparated by density, Cooper et al. (1976) found that polyamine levels in old erythrocytes were significantly less than in young erythrocytes. Consequently, since most of erythrocyte components lost during aging are membrane associated, polyamines may be associated mostly with the cell membrane. However, the polyamine levels in whole white ghost erythrocyte membranes from control subjects were only 1.5% to 2.0% of those in the soluble fraction, and showed no significant difference from those from cancer patients who had raised levels of polyamines (Takami & Nishioka, unpublished) . Further studies are in progress to determine the binding site of tumourreleased polyamines on to the erythrocytes.
Although polyamine levels are also high in patients with diseases other than cancer (Dreyfuss et al., 1975; Waalkes et al., 1975) the possible clinical application of polyamines as a useful biological marker of cancer make such a study a promising venture.
